The DOI matches its Crossref record; 310 of the 310 references it cites were found in a registry or an index.
Nanobodies as therapeutics: big opportunities for small antibodies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Sepsis and Septic Shock
Angus, D. C., & van der Poll, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208623 · Cited by 3,961
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Antibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Mechanisms of Antimicrobial Resistance in Bacteria
Tenover, F. C. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.011 · Cited by 1,682
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Goedert, M. (2015) · Science · doi:10.1126/science.1255555 · Cited by 976
A general protocol for the generation of Nanobodies for structural biology
Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G. F., Wohlkönig, A., Ruf, A., Muyldermans, S., Hol, W. G. J., Kobilka, B. K., & Steyaert, J. (2014) · Nature Protocols · doi:10.1038/nprot.2014.039 · Cited by 790
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 768
Significance of antibiotics in the environment
Kummerer, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg293 · Cited by 745
Targeting and tracing antigens in live cells with fluorescent nanobodies
Rothbauer, U., Zolghadr, K., Tillib, S., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N., Conrath, K., Muyldermans, S., Cardoso, M. C., et al. (2006) · Nature Methods · doi:10.1038/nmeth953 · Cited by 710
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505379103 · Cited by 676
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Cataland, S., Knöbl, P., Wu, H., Artoni, A., Westwood, J.-P., Mansouri Taleghani, M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 666
Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 651
Lipman, N. S., Jackson, L. R., Trudel, L. J., & Weis-Garcia, F. (2005) · ILAR Journal · doi:10.1093/ilar.46.3.258 · Cited by 644
Single‐domain antibody fragments with high conformational stability
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G. J., Muyldermans, S., Wyns, L., & Matagne, A. (2002) · Protein Science · doi:10.1110/ps.34602 · Cited by 638
Mechanisms of antimicrobial resistance in bacteria
Tenover, F. C. (2006) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.05.219 · Cited by 637
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., van Bergen en Henegouwen, P. M. P., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 625
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., & Conrath, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806889200 · Cited by 572
Sortagging: a versatile method for protein labeling
Popp, M. W., Antos, J. M., Grotenbreg, G. M., Spooner, E., & Ploegh, H. L. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.31 · Cited by 541
Camelid immunoglobulins and nanobody technology
Muyldermans, S., Baral, T. N., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.299 · Cited by 533
Potent enzyme inhibitors derived from dromedary heavy-chain antibodies
Lauwereys, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3512 · Cited by 490
Antibody fragments: Hope and hype
Nelson, A. L. (2010) · mAbs · doi:10.4161/mabs.2.1.10786 · Cited by 463
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Nanobody-based products as research and diagnostic tools
De Meyer, T., Muyldermans, S., & Depicker, A. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.03.001 · Cited by 445
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Van de Broek, B., Devoogdt, N., D’Hollander, A., Gijs, H.-L., Jans, K., Lagae, L., Muyldermans, S., Maes, G., & Borghs, G. (2011) · ACS Nano · doi:10.1021/nn1023363 · Cited by 374
Cao, L., Liu, X., Lin, E.-J. D., Wang, C., Choi, E. Y., Riban, V., Lin, B., & During, M. J. (2010) · Cell · doi:10.1016/j.cell.2010.05.029 · Cited by 369
β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae
Conrath, K. E., Lauwereys, M., Galleni, M., Matagne, A., Frère, J.-M., Kinne, J., Wyns, L., & Muyldermans, S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2807-2812.2001 · Cited by 347
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 346
Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions
Guimaraes, C. P., Witte, M. D., Theile, C. S., Bozkurt, G., Kundrat, L., Blom, A. E. M., & Ploegh, H. L. (2013) · Nature Protocols · doi:10.1038/nprot.2013.101 · Cited by 345
Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer
Vaneycken, I., Devoogdt, N., Van Gassen, N., Vincke, C., Xavier, C., Wernery, U., Muyldermans, S., Lahoutte, T., & Caveliers, V. (2011) · The FASEB Journal · doi:10.1096/fj.10-180331 · Cited by 315
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Coppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303
Movahedi, K., Schoonooghe, S., Laoui, D., Houbracken, I., Waelput, W., Breckpot, K., Bouwens, L., Lahoutte, T., De Baetselier, P., Raes, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2994 · Cited by 291
Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., et al. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.116 · Cited by 289
Nanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 288
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
Zuchero, Y. J. Y., Chen, X., Bien-Ly, N., Bumbaca, D., Tong, R. K., Gao, X., Zhang, S., Hoyte, K., Luk, W., Huntley, M. A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.024 · Cited by 282
Detalle, L., Stohr, T., Palomo, C., Piedra, P. A., Gilbert, B. E., Mas, V., Millar, A., Power, U. F., Stortelers, C., Allosery, K., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01802-15 · Cited by 279
Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans, S., & Magez, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307341200 · Cited by 276
Nanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M., Dorresteijn, B., Oliveira, S., & van Bergen en Henegouwen, P. M. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 265
Muruganandam, A., Tanha, J., Narang, S., & Stanimirovic, D. (2002) · The FASEB Journal · doi:10.1096/fj.01-0343fje · Cited by 260
Koffie, R. M., Farrar, C. T., Saidi, L.-J., William, C. M., Hyman, B. T., & Spires-Jones, T. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111405108 · Cited by 260
Jähnichen, S., Blanchetot, C., Maussang, D., Gonzalez-Pajuelo, M., Chow, K. Y., Bosch, L., De Vrieze, S., Serruys, B., Ulrichts, H., Vandevelde, W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012865107 · Cited by 250
Strategies to improve drug development for sepsis
Fink, M. P., & Warren, H. S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4368 · Cited by 242
HDL in Infectious Diseases and Sepsis
Pirillo, A., Catapano, A. L., & Norata, G. D. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-09665-0_15 · Cited by 237
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
Xavier, C., Vaneycken, I., D’huyvetter, M., Heemskerk, J., Keyaerts, M., Vincke, C., Devoogdt, N., Muyldermans, S., Lahoutte, T., & Caveliers, V. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111021 · Cited by 230
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
D'Huyvetter, M., Vincke, C., Xavier, C., Aerts, A., Impens, N., Baatout, S., De Raeve, H., Muyldermans, S., Caveliers, V., Devoogdt, N., et al. (2014) · Theranostics · doi:10.7150/thno.8156 · Cited by 225
Nanobodies and recombinant binders in cell biology
Helma, J., Cardoso, M. C., Muyldermans, S., & Leonhardt, H. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201409074 · Cited by 224
Olafsen, T., & Wu, A. M. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.12.005 · Cited by 223
Gainkam, L. O. T., Huang, L., Caveliers, V., Keyaerts, M., Hernot, S., Vaneycken, I., Vanhove, C., Revets, H., De Baetselier, P., & Lahoutte, T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048538 · Cited by 222
Habicht, G., Haupt, C., Friedrich, R. P., Hortschansky, P., Sachse, C., Meinhardt, J., Wieligmann, K., Gellermann, G. P., Brodhun, M., Götz, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703793104 · Cited by 218
Noninvasive imaging of immune responses
Rashidian, M., Keliher, E. J., Bilate, A. M., Duarte, J. N., Wojtkiewicz, G. R., Jacobsen, J. T., Cragnolini, J., Swee, L. K., Victora, G. D., Weissleder, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502609112 · Cited by 218
Abulrob, A., Sprong, H., En Henegouwen, P. V. B., & Stanimirovic, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03463.x · Cited by 216
Imaging of opioid receptors in the central nervous system
Henriksen, G., & Willoch, F. (2008) · Brain · doi:10.1093/brain/awm255 · Cited by 214
Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1
Eugster, H.-P., Frei, K., Bachmann, R., Bluethmann, H., Lassmann, H., & Fontana, A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199902)29:02<626::aid-immu626>3.0.co;2-a · Cited by 213
Targeting tumors with nanobodies for cancer imaging and therapy
Oliveira, S., Heukers, R., Sornkom, J., Kok, R. J., & van Bergen en Henegouwen, P. M. P. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.298 · Cited by 206
Li, T., Bourgeois, J., Celli, S., Glacial, F., Le Sourd, A., Mecheri, S., Weksler, B., Romero, I., Couraud, P., Rougeon, F., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-201384 · Cited by 202
Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions
Broisat, A., Hernot, S., Toczek, J., De Vos, J., Riou, L. M., Martin, S., Ahmadi, M., Thielens, N., Wernery, U., Caveliers, V., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.265140 · Cited by 200
Non-immunoglobulin scaffolds: a focus on their targets
Škrlec, K., Štrukelj, B., & Berlec, A. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.03.012 · Cited by 199
Thermal Unfolding of a Llama Antibody Fragment: A Two-State Reversible Process
Pérez, J. M. J., Renisio, J. G., Prompers, J. J., van Platerink, C. J., Cambillau, C., Darbon, H., & Frenken, L. G. J. (2001) · Biochemistry · doi:10.1021/bi0009082 · Cited by 199
Hultberg, A., Temperton, N. J., Rosseels, V., Koenders, M., Gonzalez-Pajuelo, M., Schepens, B., Ibañez, L. I., Vanlandschoot, P., Schillemans, J., Saunders, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017665 · Cited by 195
Oliveira, S., van Dongen, G. A. M. S., Walsum, M. S.-V., Roovers, R. C., Stam, J. C., Mali, W., van Diest, P. J., & van Bergen en Henegouwen, P. M. P. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194
SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression
Huang, L., Gainkam, L. O. T., Caveliers, V., Vanhove, C., Keyaerts, M., De Baetselier, P., Bossuyt, A., Revets, H., & Lahoutte, T. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-008-0133-8 · Cited by 192
Structure and Properties of a Complex of α-Synuclein and a Single-Domain Camelid Antibody
De Genst, E. J., Guilliams, T., Wellens, J., O'Day, E. M., Waudby, C. A., Meehan, S., Dumoulin, M., Hsu, S.-T. D., Cremades, N., Verschueren, K. H. G., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.07.001 · Cited by 186
Massa, S., Xavier, C., De Vos, J., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500111t · Cited by 184
Goldman, E. R., Anderson, G. P., Liu, J. L., Delehanty, J. B., Sherwood, L. J., Osborn, L. E., Cummins, L. B., & Hayhurst, A. (2006) · Analytical Chemistry · doi:10.1021/ac0610053 · Cited by 183
Van Roy, M., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., Breedveld, E., ‘t Hart, B., Poelmans, S., Bontinck, L., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0651-0 · Cited by 180
Clinical Implications of Near-Infrared Fluorescence Imaging in Cancer
Kosaka, N., Ogawa, M., Choyke, P. L., & Kobayashi, H. (2009) · Future Oncology · doi:10.2217/fon.09.109 · Cited by 179
Systemic Inflammatory Response Syndrome (SIRS): Molecular Pathophysiology and Gene Therapy
Matsuda, N., & Hattori, Y. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj06010x · Cited by 178
Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor
Baral, T. N., Magez, S., Stijlemans, B., Conrath, K., Vanhollebeke, B., Pays, E., Muyldermans, S., & De Baetselier, P. (2006) · Nature Medicine · doi:10.1038/nm1395 · Cited by 166
Biotechnological applications of recombinant single-domain antibody fragments
de Marco, A. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-44 · Cited by 166
Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics
Xiao, G., & Gan, L.-S. (2013) · International Journal of Cell Biology · doi:10.1155/2013/703545 · Cited by 163
Papadopoulos, K. P., Isaacs, R., Bilic, S., Kentsch, K., Huet, H. A., Hofmann, M., Rasco, D., Kundamal, N., Tang, Z., Cooksey, J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2712-0 · Cited by 162
Downregulation of EGFR by a novel multivalent nanobody-liposome platform
Oliveira, S., Schiffelers, R. M., van der Veeken, J., van der Meel, R., Vongpromek, R., Henegouwen, P. M. P. V. B. E., Storm, G., & Roovers, R. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.020 · Cited by 161
Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability
Hussack, G., Hirama, T., Ding, W., MacKenzie, R., & Tanha, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028218 · Cited by 160
Blykers, A., Schoonooghe, S., Xavier, C., D’hoe, K., Laoui, D., D’Huyvetter, M., Vaneycken, I., Cleeren, F., Bormans, G., Heemskerk, J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156828 · Cited by 160
Wang, D., El-Amouri, S. S., Dai, M., Kuan, C.-Y., Hui, D. Y., Brady, R. O., & Pan, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222742110 · Cited by 159
Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., van Walsum, M., Revets, H., & van Dongen, G. A. M. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0891 · Cited by 158
Pant, N., Hultberg, A., Zhao, Y., Svensson, L., Pan‐Hammarström, Q., Johansen, K., Pouwels, P. H., Ruggeri, F. M., Hermans, P., Frenken, L. G. J., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/508747 · Cited by 158
Hussack, G., Arbabi‐Ghahroudi, M., van Faassen, H., Songer, J. G., Ng, K. K.-S., MacKenzie, R., & Tanha, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.198754 · Cited by 157
A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics
Farrington, G. K., Caram‐Salas, N. L., Haqqani, A. S., Brunette, E., Eldredge, J. K., Pepinsky, B., Antognetti, G., Baumann, E., Ding, W., Garber, E. A., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-253369 · Cited by 154
Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1
Hauwermeiren, F. V., Vandenbroucke, R. E., & Libert, C. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.09.004 · Cited by 151
Self-citationMaussang, D., Mujić-Delić, A., Descamps, F. J., Stortelers, C., Vanlandschoot, P., van Walsum, M., Vischer, H. F., Roy, M. V., Vosjan, M. J. W. D., González-Pajuelo, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498436 · Cited by 148
The development of nanobodies for therapeutic applications.
Bockstaele, F. V., Holz, J.-B., & Revets, H. (2009) · PubMed · Cited by 145
Hmila, I., Abderrazek, R. B., Saerens, D., Benlasfar, Z., Conrath, K., Ayeb, M. E., Muyldermans, S., & Bouhaouala‐Zahar, B. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.04.011 · Cited by 144
Nanobodies®: New ammunition to battle viruses
Vanlandschoot, P., Stortelers, C., Beirnaert, E., Ibañez, L. I., Schepens, B., Depla, E., & Saelens, X. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.09.002 · Cited by 144
Isolation of Llama Antibody Fragments for Prevention of Dandruff by Phage Display in Shampoo
Dolk, E., van der Vaart, M., Hulsik, D. L., Vriend, G., de Haard, H., Spinelli, S., Cambillau, C., Frenken, L. G. J., & Verrips, T. C. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.1.442-450.2005 · Cited by 144
Chatalic, K. L. S., Veldhoven-Zweistra, J., Bolkestein, M., Hoeben, S. A. H., Koning, G. A., Boerman, O. C., de Jong, M., & van Weerden, W. M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156729 · Cited by 144
Immuno-imaging using nanobodies
Vaneycken, I., D’Huyvetter, M., Hernot, S., Vos, J. D., Xavier, C., Devoogdt, N., Caveliers, V., & Lahoutte, T. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.009 · Cited by 142
Callewaert, F., Roodt, J. P., Ulrichts, H., Stöhr, T., van Rensburg, W. J. J., Lamprecht, S., Rossenu, S., Priem, S., Willems, W. F., & Holz, J.-B. (2012) · Blood · doi:10.1182/blood-2012-04-420943 · Cited by 142
Vos, J. D., Devoogdt, N., Lahoutte, T., & Muyldermans, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.800478 · Cited by 138
Sharkey, R. M., & Goldenberg, D. M. (2011) · Immunotherapy · doi:10.2217/imt.10.114 · Cited by 138
Structures of G protein-coupled receptors reveal new opportunities for drug discovery
Cooke, R. M., Brown, A., Marshall, F. H., & Mason, J. S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.003 · Cited by 133
Yau, K. Y. F., Groves, M. A. T., Li, S., Sheedy, C., Lee, H., Tanha, J., MacKenzie, C. R., Jermutus, L., & Hall, J. C. (2003) · Journal of Immunological Methods · doi:10.1016/j.jim.2003.07.011 · Cited by 132
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 132
Lafaye, P. J., Achour, I., England, P., Duyckaerts, C. J., & Rougeon, F. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.09.008 · Cited by 131
Vosjan, M. J. W. D., Perk, L. R., Roovers, R. C., Visser, G. W. M., van Walsum, M., Henegouwen, P. M. P. V. B. E., & van Dongen, G. A. M. S. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1700-1 · Cited by 128
Vaneycken, I., Govaert, J., Vincke, C., Caveliers, V., Lahoutte, T., BAETSELIER, P. D., Raes, G., Bossuyt, A. M., Muyldermans, S., & Devoogdt, N. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069823 · Cited by 128
Nanobodies With In Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection
Ibañez, L. I., Filette, M. D., Hultberg, A., Verrips, T. C., Temperton, N. J., Weiss, R. A., Vandevelde, W., Schepens, B., Vanlandschoot, P., & Saelens, X. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq168 · Cited by 127
Differential tumor-targeting abilities of three single-domain antibody formats
Bell, A., Wang, Z. J., Arbabi‐Ghahroudi, M., Chang, T.-T. A., Durocher, Y., Trojahn, U., Baardsnes, J., Jaramillo, M., Li, S., Baral, T. N., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.08.003 · Cited by 126
A bispecific nanobody to provide full protection against lethal scorpion envenoming
Hmila, I., Saerens, D., Abderrazek, R. B., Vincke, C., Abidi, N., Benlasfar, Z., Govaert, J., Ayeb, M. E., Bouhaouala‐Zahar, B., & Muyldermans, S. (2010) · The FASEB Journal · doi:10.1096/fj.09-148213 · Cited by 125
Harmsen, M. M., van Solt, C. B., Bemmel, A. M. V. Z.-V., Niewold, T., & van Zijderveld, F. G. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-0300-7 · Cited by 125
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
D’Huyvetter, M., Xavier, C., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.941803 · Cited by 124
Richard, G., Meyers, A. J., McLean, M. D., Arbabi‐Ghahroudi, M., MacKenzie, R., & Hall, J. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069495 · Cited by 124
Vandenbroucke, R. E., Dejonckheere, E., Lint, P. V., Demeestere, D., Wonterghem, E. V., Vanlaere, I., Puimège, L., Hauwermeiren, F. V., Rycke, R. M. D., Guire, C. M., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0967-12.2012 · Cited by 122
Self-citationAltıntaş, I., Heukers, R., van der Meel, R., Lacombe, M., Amidi, M., Henegouwen, P. M. P. V. B. E., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.007 · Cited by 121
Abskharon, R. N. N., Giachin, G., Wohlkönig, A., Soror, S. H. A., Pardon, E., Legname, G., & Steyaert, J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja407527p · Cited by 120
Molecular and metabolic imaging of atherosclerosis.
Davies, J. R., Rudd, J. H. F., & Weissberg, P. L. (2004) · PubMed · Cited by 119
Mullard, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4545 · Cited by 119
Domanska, K., Vanderhaegen, S., Srinivasan, V., Pardon, E., Dupeux, F., Márquez, J. A., Giorgetti, S., Stoppini, M., Wyns, L., Bellotti, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008560108 · Cited by 119
Guilliams, T., El-Turk, F., Buell, A. K., O’Day, E. M., Aprile, F. A., Esbjörner, E. K., Vendruscolo, M., Cremades, N., Pardon, E., Wyns, L., et al. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.01.040 · Cited by 118
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
Zhang, G., Wang, L., Cui, H., Wang, X., Zhang, G., Ma, J., Han, H., He, W., Wang, W., Zhao, Y., et al. (2014) · Scientific Reports · doi:10.1038/srep03571 · Cited by 117
Huet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M. R., Kowal, C., Yang, G., Royo, A., et al. (2014) · mAbs · doi:10.4161/19420862.2014.975099 · Cited by 116
Tanaka, T. U., Lobato, M. N., & Rabbitts, T. H. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00836-2 · Cited by 114
Vandervaart, J. P., Pant, N., Wolvers, D. A. W., Bezemer, S., Hermans, P., Bellamy, K., Sarker, S. A., VANDERLOGT, C., Svensson, L., & Verrips, C. T. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.02.045 · Cited by 112
Nanobody–photosensitizer conjugates for targeted photodynamic therapy
Heukers, R., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.12.007 · Cited by 111
Latest technologies for the enhancement of antibody affinity
Wark, K. L., & Hudson, P. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.025 · Cited by 110
A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis
Impe, K. V., Bethuyne, J., Cool, S. K., Impens, F., Ruano‐Gallego, D., Wever, O. D., Vanloo, B., Troys, M. V., Lambein, K., Boucherie, C., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3585 · Cited by 109
Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types
Groeve, K. D., Deschacht, N., Koninck, C. D., Caveliers, V., Lahoutte, T., Devoogdt, N., Muyldermans, S., BAETSELIER, P. D., & Raes, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070078 · Cited by 108
Yang, Z., Schmidt, D., Liu, W., Li, S., Shi, L., Sheng, J., Chen, K., Yu, H., Tremblay, J. M., Chen, X., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu196 · Cited by 107
van der Meel, R., Oliveira, S., Altıntaş, I., Haselberg, R., van der Veeken, J., Roovers, R. C., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Schiffelers, R. M., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.027 · Cited by 105
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody
Pruszyński, M., Koumarianou, E., Vaidyanathan, G., Revets, H., Devoogdt, N., Lahoutte, T., & Zalutsky, M. R. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.08.008 · Cited by 105
GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics
Mujić-Delić, A., de Wit, R. H., Verkaar, F., & Smit, M. J. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.03.003 · Cited by 105
A New Means of Inducibly Inactivating a Cellular Protein
Carlson, J. R. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.6.2638-2646.1988 · Cited by 105
Bala, G., Blykers, A., Xavier, C., Descamps, B., Broisat, A., Ghezzi, C., Fagret, D., Camp, G. V., Caveliers, V., Vanhove, C., et al. (2016) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jev346 · Cited by 105
Gebauer, M., & Skerra, A. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00007-0 · Cited by 104
Sha, H., Zou, Z., Xin, K., Bian, X., Cai, X., Lu, W., Chen, J., Chen, G., Huang, L., Blair, A. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.039 · Cited by 104
Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate
Transue, T. R., Genst, E. D., Ghahroudi, M. A., Wyns, L., & Muyldermans, S. (1998) · Proteins Structure Function and Bioinformatics · Cited by 103
Rakovich, T. Y., Mahfoud, O. K., Mohamed, B. M., Prina‐Mello, A., Crosbie-Staunton, K., Broeck, T. V. D., Kimpe, L. D., Sukhanova, A. V., Baty, D., Rakovich, A., et al. (2014) · ACS Nano · doi:10.1021/nn500212h · Cited by 103
Tremblay, J. M., Mukherjee, J., Leysath, C. E., Debatis, M. E., Ofori, K., Baldwin, K., Boucher, C., Peters, R., Beamer, G., Sheoran, A. S., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01033-13 · Cited by 102
Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression
Dejonckheere, E., Vandenbroucke, R. E., & Libert, C. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.002 · Cited by 102
Self-citationBéhar, G., Sibéril, S., Groulet, A., Chames, P., Pugnière, M., Boix, C., Sautès‐Fridman, C., Teillaud, J., & Baty, D. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm064 · Cited by 99
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
Lemaire, M., D’Huyvetter, M., Lahoutte, T., Valckenborgh, E. V., Menu, E., Bruyne, E. D., Kronenberger, P., Wernery, U., Muyldermans, S., Devoogdt, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.292 · Cited by 98
Nanobody-coupled microbubbles as novel molecular tracer
Hernot, S., Unnikrishnan, S., Du, Z., Shevchenko, T. I., Cosyns, B., Broisat, A., Toczek, J., Caveliers, V., Muyldermans, S., Lahoutte, T., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.007 · Cited by 98
A novel role for matrix metalloproteinase-8 in sepsis*
Solan, P. D., Dunsmore, K. E., Denenberg, A. G., Odoms, K., Zingarelli, B., & Wong, H. R. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318232e404 · Cited by 97
Vaidyanathan, G., McDougald, D. L., Choi, J., Koumarianou, E., Weitzel, D. H., Osada, T., Lyerly, H. K., & Zalutsky, M. R. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171306 · Cited by 97
Zhu, M., Gong, X., Hu, Y., Ou, W., & Wan, Y. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0352-5 · Cited by 96
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
van de Water, J. A. J. M., Onder, T. B., Agarwal, A. S., Wakimoto, H., Roovers, R. C., Zhu, Y., Kasmieh, R., Bhere, D., Henegouwen, P. M. P. V. B. E., & Shah, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202832109 · Cited by 95
Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
Bartúnek, J., Barbato, E., Heyndrickx, G. R., Vanderheyden, M., Wijns, W. C., & Holz, J.-B. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9435-y · Cited by 95
High efficiency cell-specific targeting of cytokine activity
Garcin, G., Paul, F., Staufenbiel, M., Bordat, Y., der Heyden, J. V., Wilmes, S., Cartron, G., Apparailly, F., Koker, S. D., Piehler, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4016 · Cited by 95
Fang, T., Duarte, J. N., Ling, J. J., Li, Z., Guzman, J. S., & Ploegh, H. L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201509432 · Cited by 95
Bradley, M., Dombrecht, B., Manini, J., Willis, J. R., Vlerick, D., Taeye, S. D., den Heede, K. V., Roobrouck, A., Grot, E., Kent, T. C., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094821 · Cited by 94
Verheesen, P., de Kluijver, A., van Koningsbruggen, S., de Brij, M., de Haard, H., van Ommen, G. B., van der Maarel, S. M., & Verrips, C. T. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi432 · Cited by 94
Jamnani, F. R., Rahbarizadeh, F., Shokrgozar, M. A., Mahboudi, F., Ahmadvand, D., Sharifzadeh, Z., Parhamifar, L., & Moghimi, S. M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.09.029 · Cited by 93
Put, S., Schoonooghe, S., Devoogdt, N., Schurgers, E., Avau, A., Mitera, T., D’Huyvetter, M., BAETSELIER, P. D., Raes, G., Lahoutte, T., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111781 · Cited by 93
van Driel, P. B. A. A., van der Vorst, J. R., Verbeek, F. P. R., Oliveira, S., Snoeks, T. J. A., Keereweer, S., Chan, A. B., Boonstra, M. C., Frangioni, J. V., Henegouwen, P. M. P. V. B. E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28601 · Cited by 92
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection
Tokuhara, D., Álvarez, B., Mejima, M., Hiroiwa, T., Takahashi, Y., Kurokawa, S., Kuroda, M., Oyama, M., Kozuka‐Hata, H., Nochi, T., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70266 · Cited by 90
Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?
Waldmeier, P. C., & Tatton, W. G. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03000-9 · Cited by 89
Behdani, M., Zeinali, S., Karimipour, M., Khanahmad, H., Schoonooghe, S., Aslemarz, A., Seyed, N., Moazzami, R., Baniahmad, F., Habibi‐Anbouhi, M., et al. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.09.002 · Cited by 89
Generation of heavy-chain-only antibodies in mice
Janssens, R., Dekker, S., Hendriks, R. W., Panayotou, G., van Remoortere, A., San, J. K. A., Grosveld, F. G., & Drabek, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601108103 · Cited by 89
Pruszyński, M., Koumarianou, E., Vaidyanathan, G., Revets, H., Devoogdt, N., Lahoutte, T., Lyerly, H. K., & Zalutsky, M. R. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.127100 · Cited by 89
Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis
Arias, J. L., Unciti-Broceta, J. D., Maceira, J., del Castillo, T., Hernández-Quero, J., Magez, S., Soriano, M., & García-Salcedo, J. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.002 · Cited by 88
Immunization delivered by lentiviral vectors for cancer and infectious diseases
Hu, B., Tai, A., & Wang, P. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00967.x · Cited by 88
Intrabody applications in neurological disorders: progress and future prospects
Miller, T. W., & Messer, A. C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.003 · Cited by 88
Harmsen, M. M., van Solt, C. B., Fijten, H., & Setten, M. C. V. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.05.017 · Cited by 87
Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis
Deckers, N., Saerens, D., Kanobana, K., Conrath, K., Victor, B., Wernery, U., Vercruysse, J., Muyldermans, S., & Dorny, P. (2008) · International Journal for Parasitology · doi:10.1016/j.ijpara.2008.10.012 · Cited by 86
Koide, A., Tereshko, V., Uysal, S., Margalef, K., Kossiakoff, A. A., & Koide, S. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.08.027 · Cited by 85
An Alpaca Nanobody Inhibits Hepatitis C Virus Entry And Cell-To-Cell Transmission
Tarr, A. W., Lafaye, P. J., Meredith, L. W., Damier-Piolle, L., Urbanowicz, R. A., Meola, A., Jestin, J., Brown, R. J. P., McKeating, J. A., Rey, F. A., et al. (2013) · Hepatology · doi:10.1002/hep.26430 · Cited by 83
Heukers, R., Altıntaş, I., Raghoenath, S., Zan, E. D., Pepermans, R. A., Roovers, R. C., Haselberg, R., Hennink, W. E., Schiffelers, R. M., Kok, R. J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.001 · Cited by 83
Holland, M. C., Würthner, J., Morley, P. J., Birchler, M., Lambert, J., Albayaty, M., Serone, A., Wilson, R., Chen, Y., Forrest, R. M., et al. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9915-0 · Cited by 82
Steeland, S., Puimège, L., Vandenbroucke, R. E., Hauwermeiren, F. V., Haustraete, J., Devoogdt, N., Hulpiau, P., Leroux-Roels, G. G., Laukens, D., Meuleman, P., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.617787 · Cited by 82
Self-citationRozan, C., Cornillon, A., Pétiard, C., Chartier, M., Béhar, G., Boix, C., Kerfélec, B., Robert, B., Pèlegrin, A., Chames, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1012 · Cited by 81
Fan, X., Wang, L., Guo, Y., Tu, Z., Li, L., Tong, H., Xu, Y., Li, R., & Fang, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127419 · Cited by 79
Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis
Unciti-Broceta, J. D., Arias, J. L., Maceira, J., Soriano, M., Ortiz-González, M., Hernández‐Quero, J., Muñoz‐Torres, M., de Koning, H. P., Magez, S., & Garcia-Salcedo, J. A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004942 · Cited by 79
Vercruysse, T., Pardon, E., Vanstreels, E., Steyaert, J., & Daelemans, D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.112490 · Cited by 79
Inhaler technique and patient's preference for dry powder inhaler devices
Lavorini, F., & Fontana, G. A. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.846907 · Cited by 79
Kaiser, P. D., Maier, J., Traenkle, B., Emele, F. E., & Rothbauer, U. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.04.019 · Cited by 78
Engineering and Pharmacology of Blood–Brain Barrier-Permeable Bispecific Antibodies
Stanimirovic, D. B., Kemmerich, K., Haqqani, A. S., & Farrington, G. K. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.005 · Cited by 77
Sharifzadeh, Z., Rahbarizadeh, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., Jamnani, F. R., & Moghimi, S. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.010 · Cited by 76
Ashour, J., Schmidt, F. I., Hanke, L., Cragnolini, J., Cavallari, M., Altenburg, A. F., Brewer, R. C., Ingram, J. R., Shoemaker, C. B., & Ploegh, H. L. (2014) · Journal of Virology · doi:10.1128/jvi.02693-14 · Cited by 76
Liu, H., Wang, Y., Duan, H. Q., Zhang, A., Liang, C., Gao, J., Zhang, C., Huang, B., Li, Q., Li, N., et al. (2015) · Veterinary Microbiology · doi:10.1016/j.vetmic.2015.10.021 · Cited by 76
Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy
Ding, L. J., Tian, C., Feng, S., Fida, G., Zhang, C., Ma, Y., Ai, G., Achilefu, S., & Gu, Y. (2015) · Theranostics · doi:10.7150/thno.10084 · Cited by 76
Unger, M., Eichhoff, A. M., Schumacher, L., Strysio, M., Menzel, S., Schwan, C., Alzogaray, V., Zylberman, V., Séman, M., Brandner, J. M., et al. (2015) · Scientific Reports · doi:10.1038/srep07850 · Cited by 75
Hereditary gelsolin amyloidosis
Kiuru‐Enari, S., & Haltia, M. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52902-2.00039-4 · Cited by 74
Yan, J., Wang, P., Zhu, M., Li, G., Romão, E., Xiong, S., & Wan, Y. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0091-7 · Cited by 74
A nanobody-based electrochemiluminescent immunosensor for sensitive detection of human procalcitonin
Li, H., Sun, Y., Elseviers, J., Muyldermans, S., Liu, S., & Wan, Y. (2014) · The Analyst · doi:10.1039/c4an00626g · Cited by 74
Genetic therapy for the nervous system
Bowers, W. J., Breakefield, X. O., & Sena‐Esteves, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr110 · Cited by 74
Vooght, L. D., Caljon, G., Stijlemans, B., BAETSELIER, P. D., Coosemans, M., & Abbeele, J. V. D. (2012) · Microbial Cell Factories · doi:10.1186/1475-2859-11-23 · Cited by 74
Sarker, S. A., Jäkel, M., Sultana, S., Alam, N. H., Bardhan, P. K., Chisti, M. J., Salam, M. A., Theis, W., Hammarström, L. L. G., & Frenken, L. G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.053 · Cited by 74
Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management
Velikyan, I. (2012) · Theranostics · doi:10.7150/thno.4428 · Cited by 73
Clinical review: Sepsis and septic shock - the potential of gene arrays
Wong, H. R. (2012) · Critical Care · doi:10.1186/cc10537 · Cited by 73
Nanobody Binding to a Conserved Epitope Promotes Norovirus Particle Disassembly
Koromyslova, A. D., & Hansman, G. S. (2014) · Journal of Virology · doi:10.1128/jvi.03176-14 · Cited by 72
Goyvaerts, C., Groeve, K. D., Dingemans, J., Lint, S. V., Robays, L. J., Heirman, C., Reiser, J., Zhang, X.-Y., Thielemans, K., BAETSELIER, P. D., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.206 · Cited by 71
Vance, D. J., Tremblay, J. M., Mantis, N. J., & Shoemaker, C. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519207 · Cited by 70
Cytokine–receptor interactions as drug targets
Schreiber, G., & Walter, M. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.165 · Cited by 70
Evazalipour, M., D’Huyvetter, M., Tehrani, B. S., Abolhassani, M., Omidfar, K., Abdoli, S., Arezumand, R., Morovvati, H., Lahoutte, T., Muyldermans, S., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1558 · Cited by 70
Vooght, L. D., Caljon, G., Ridder, K. D., & Abbeele, J. V. D. (2014) · Microbial Cell Factories · doi:10.1186/s12934-014-0156-6 · Cited by 69
Cited by
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Point-of-Care Diagnostics: Recent Developments in a Connected Age
Nayak, S., Blumenfeld, N. R., Laksanasopin, T., & Sia, S. K. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04630 · Cited by 508
Guo, K., Wustoni, S., Koklu, A., Díaz-Galicia, E., Moser, M., Hama, A., Alqahtani, A. A., Ahmad, A. N., Alhamlan, F. S., Shuaib, M., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00734-9 · Cited by 410
Purine Release, Metabolism, and Signaling in the Inflammatory Response
Linden, J., Koch-Nolte, F., & Dahl, G. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052406 · Cited by 377
Metadata
- Authors
- Steeland, S., Vandenbroucke, R. E., & Libert, C.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 21
- Issue
- 7
- Pages
- 1076-1113
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2325393979
- Cited by
- 468
- References
- 310
- FWCI
- 30.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.